References
- Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in
Children. N Engl J Med . 2015;373(16):1541-1552.
doi:10.1056/NEJMra1400972
- Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell
transplantation in children with acute lymphoblastic leukemia: A
prospective international multicenter trial comparing sibling donors
with matched unrelated donors-The ALL-SCT-BFM-2003 trial. J Clin
Oncol . 2015;33(11):1265-1274. doi:10.1200/JCO.2014.58.9747
- Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A. Early lymphocyte
recovery post-allogeneic hematopoietic stem cell transplantation is
associated with significant graft-versus-leukemia effect without
increase in graft-versus-host disease in pediatric acute lymphoblastic
leukemia. Bone Marrow Transplant . 2008;41(3):245-252.
doi:10.1038/sj.bmt.1705891
- Pulsipher M, Peters C, Pui C. High-Risk Pediatric Acute Lymphoblastic
Leukemia: To Transplant or Not to Transplant? Biol blood marrow
transplant . 2011;17:s137-s148. doi:10.1016/j.bbmt.2010.10.005
- Sakellari I, Gavriilaki E, Chatziioannou K, et al. Long-term outcomes
of total body irradiation plus cyclophosphamide versus busulfan plus
cyclophosphamide as conditioning regimen for acute lymphoblastic
leukemia: a comparative study. Ann Hematol .
2018;97(10):1987-1994. doi:10.1007/s00277-018-3383-9
- Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with
acute leukemia treated by chemotherapy, total body irradiation, and
allogeneic marrow transplantation. Blood . 1977;49(4):511-533.
- Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant .
2009;15(5):523-536. doi:10.1016/j.bbmt.2008.12.489
- Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized
trial of busulfan vs total body irradiation containing conditioning
regimens for children with acute lymphoblastic leukemia: a Pediatric
Blood and Marrow Transplant Consortium study. Bone Marrow
Transplant . 2003;32(6):543-548. doi:10.1038/sj.bmt.1704198
- Vassal G, Michel G, Espérou H, et al. Prospective validation of a
novel IV busulfan fixed dosing for paediatric patients to improve
therapeutic AUC targeting without drug monitoring. Cancer
Chemother Pharmacol . 2008;61(1):113-123.
doi:10.1007/s00280-007-0455-2
- Tse WT, Duerst R, Schneiderman J, Chaudhury S, Jacobsohn D, Kletzel M.
Age-dependent pharmacokinetic profile of single daily dose i.v.
busulfan in children undergoing reduced-intensity conditioning stem
cell transplant. Bone Marrow Transplant . 2009;44(3):145-156.
doi:10.1038/bmt.2008.437
- Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic
disposition and clinical outcomes in infants and children receiving
intravenous busulfan for allogeneic hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant .
2007;13(3):307-314. doi:10.1016/j.bbmt.2006.10.026
- Wall DA, Chan KW, Nieder ML, et al. Safety, efficacy, and
pharmacokinetics of intravenous busulfan in children undergoing
allogeneic hematopoietic stem cell transplantation. Pediatr
Blood Cancer . 2010;54(2):291-298. doi:10.1002/pbc.22227
- Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan
given with fludarabine as conditioning for allogeneic stem cell
transplantation: study of pharmacokinetics and early clinical
outcomes. Biol Blood Marrow Transplant . 2002;8(9):468-476.
doi:10.1053/bbmt.2002.v8.pm12374451
- Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HL-A-matched sibling donors. Transplantation .
1974;18(4):295-304. doi:10.1097/00007890-197410000-00001
- Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health
Consensus Development Project on Criteria for Clinical Trials in
Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging
Working Group report. Biol Blood Marrow Transplant .
2015;21(3):389-401.e1. doi:10.1016/j.bbmt.2014.12.001
- Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for
adult acute leukemia in first and second remission with a novel
regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY
total-body irradiation, and thymoglobulin. Biol Blood Marrow
Transplant . 2007;13(7):814-821. doi:10.1016/j.bbmt.2007.03.003
- M.L. Savoie, A. Balogh, M.A. Chaudhry, et al. Total body irradiation
(TBI) added to fludarabine/busulfan/antithymocyte globulin
(FLUBUP/ATG) conditioning increases overall survival and relapse-free
survival in patients with acute myeloid leukemia (AML) receiving
allogeneic stem cell transplants. Blood . 2006;108 (11):3010.
https://doi.org/10.1182/blood.V108.11.3010.3010
- Willasch AM, Peters C, Sedláček P, et al. Myeloablative conditioning
for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter
EBMT-PDWP study [published correction appears in Bone Marrow
Transplant. 2021 Oct;56(10):2615]. Bone Marrow Transplant .
2020;55(8):1540-1551. doi:10.1038/s41409-020-0854-0
- Peters C, Dalle JH, Locatelli F, et al. Total Body Irradiation or
Chemotherapy Conditioning in Childhood ALL: A Multinational,
Randomized, Noninferiority Phase III Study. J Clin Oncol .
2021;39(4):295-307. doi:10.1200/JCO.20.02529
- Chaudhury S, Helenowski I, Duerst R, et al. Reduced toxicity
myeloablative conditioning regimen in pediatric hematologic
malignancies not associated with improved outcomes. Physicians –
Poster Session. Bone Marrow Transplant 52, S124–S516 (2017).
https://doi.org/10.1038/bmt.2017.134
- Rossoff J, Jacobsohn D, Kwon S, et al. Reduced-toxicity conditioning
regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric
patients undergoing hematopoietic stem cell transplant for high-risk
hematologic malignancies. Pediatr Blood Cancer .
2021;68(8):e29087. doi:10.1002/pbc.29087
- Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation
with anti-T-cell antibodies on the outcome of reduced-intensity
allogeneic hematopoietic stem cell transplantation for hematologic
malignancies. Blood . 2011;117(25):6963-6970.
doi:10.1182/blood-2011-01-332007
- Modi D, Singh V, Kim S, et al. Comparison of myeloablative and reduced
intensity conditioning unrelated donor allogeneic peripheral blood
stem cell transplant outcomes for AML using thymoglobulin for GVHD
prophylaxis. Ann Hematol . 2021;100(4):969-978.
doi:10.1007/s00277-021-04445-8
- Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from
unrelated donors are associated with increased acute and chronic
graft-versus-host disease without improved survival. Biol Blood
Marrow Transplant . 2007;13(12):1461-1468.
doi:10.1016/j.bbmt.2007.08.006
- Amouzegar A, Dey BR, Spitzer TR. Peripheral Blood or Bone Marrow Stem
Cells? Practical Considerations in Hematopoietic Stem Cell
Transplantation. Transfus Med Rev . 2019;33(1):43-50.
doi:10.1016/j.tmrv.2018.11.003
- Kawahara Y, Morimoto A, Inagaki J, et al. Unrelated cord blood
transplantation with myeloablative conditioning for pediatric acute
lymphoblastic leukemia in remission: prognostic factors. Bone
Marrow Transplant . 2021;56(2):357-367. doi:10.1038/s41409-020-01019-6
- Konuma T, Kanda J, Yamasaki S, et al. Single Cord Blood
Transplantation Versus Unmanipulated Haploidentical Transplantation
for Adults with Acute Myeloid Leukemia in Complete
Remission. Transplant Cell Ther . 2021;27(4):334.e1-334.e11.
doi:10.1016/j.jtct.2021.01.023
- Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic
Process, Prevention, and Therapy. N Engl J Med .
2017;377(22):2167-2179. doi:10.1056/NEJMra1609337
- Dalle JH, Balduzzi A, Bader P, et al. Allogeneic Stem Cell
Transplantation from HLA-Mismatched Donors for Pediatric Patients with
Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and
2007 International BFM Studies: Impact of Disease Risk on
Outcomes. Biol Blood Marrow Transplant . 2018;24(9):1848-1855.
doi:10.1016/j.bbmt.2018.05.009.
- Kumar A, Reljic T, Hamadani M, Mohty M, Kharfan-Dabaja MA.
Antithymocyte globulin for graft-versus-host disease prophylaxis: an
updated systematic review and meta-analysis. Bone Marrow
Transplant . 2019;54(7):1094-1106. doi:10.1038/s41409-018-0393-0
- Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin
for graft-versus-host disease prophylaxis in transplants from
unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti
Midollo Osseo (GITMO). Blood . 2001;98(10):2942-2947.
doi:10.1182/blood.v98.10.2942
- Silcock R, Mitchell K, Fraser C, Clark J. Epidemiology and outcome for
viremia in children undergoing bone marrow transplant: A retrospective
cohort study. Transpl Infect Dis . 2021;23(4):e13580.
doi:10.1111/tid.13580
- Tsoumakas K, Giamaiou K, Goussetis E, et al. Epidemiology of viral
infections among children undergoing hematopoietic stem cell
transplant: Α prospective single-center study. Transpl Infect
Dis . 2019;21(4):e13095. doi:10.1111/tid.13095
- Rustia E, Violago L, Jin Z, et al. Risk Factors and Utility of a
Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr
Virus, and Adenovirus Infections in Pediatric Recipients after
Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow
Transplant . 2016;22(9):1646-1653. doi:10.1016/j.bbmt.2016.05.014
- Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L.
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell
Transplantation: Risk Factors for Primary Infection and Cases of
Recurrent and Late Infection at a Single Center. Biol Blood
Marrow Transplant . 2016;22(7):1275-1283.
doi:10.1016/j.bbmt.2016.04.004
- Alexandersson A, Koskenvuo M, Tiderman A, et al. Viral infections and
immune reconstitution interaction after pediatric allogenic
hematopoietic stem cell transplantation. Infect Dis (Lond) .
2019;51(10):772-778. doi:10.1080/23744235.2019.1650198
- Castagnola E, Bagnasco F, Faraci M, et al. Incidence of bacteremias
and invasive mycoses in children undergoing allogeneic hematopoietic
stem cell transplantation: a single center experience. Bone
Marrow Transplant . 2008;41(4):339-347. doi:10.1038/sj.bmt.1705921
- Heston SM, Young RR, Hong H, et al. Microbiology of Bloodstream
Infections in Children After Hematopoietic Stem Cell Transplantation:
A Single-Center Experience Over Two Decades (1997-2017). Open
Forum Infect Dis . 2020;7(11):ofaa465. Published 2020 Sep 30.
doi:10.1093/ofid/ofaa465
- Goussetis E, Efstathiou E, Paisiou A, et al. Infectious complications
following allogeneic stem cell transplantation by using anti-thymocyte
globulin-based myeloablative conditioning regimens in children with
hemoglobinopathies. Transpl Infect Dis . 2015;17(2):201-207.
doi:10.1111/tid.12358
- Zając-Spychała O, Wachowiak J, Pieczonka A, et al. Bacterial
infections in pediatric hematopoietic stem cell transplantation
recipients: incidence, epidemiology, and spectrum of pathogens: report
of the Polish Pediatric Group for Hematopoietic Stem Cell
Transplantation. Transpl Infect Dis . 2016;18(5):690-698.
doi:10.1111/tid.12581.
- Jahan D, Peile E, Sheikh MA, et al. Is it time to reconsider
prophylactic antimicrobial use for hematopoietic stem cell
transplantation? a narrative review of antimicrobials in stem cell
transplantation. Expert Rev Anti Infect Ther .
2021;19(10):1259-1280. doi:10.1080/14787210.2021.1902304
- Bartelink IH, van Reij EM, Gerhardt CE, et al. Fludarabine and
exposure-targeted busulfan compares favorably with
busulfan/cyclophosphamide-based regimens in pediatric hematopoietic
cell transplantation: maintaining efficacy with less
toxicity. Biol Blood Marrow Transplant . 2014;20(3):345-353.
doi:10.1016/j.bbmt.2013.11.027
- Law J, Cowan MJ, Dvorak CC, et al. Busulfan, fludarabine, and
alemtuzumab as a reduced toxicity regimen for children with malignant
and nonmalignant diseases improves engraftment and graft-versus-host
disease without delaying immune reconstitution. Biol Blood
Marrow Transplant . 2012;18(11):1656-1663.
doi:10.1016/j.bbmt.2012.05.006
- Boztug H, Zecca M, Sykora KW, et al. Treosulfan-based conditioning
regimens for allogeneic HSCT in children with acute lymphoblastic
leukaemia. Ann Hematol . 2015;94(2):297-306.
doi:10.1007/s00277-014-2196-8
- Pasquini MC, Le-Rademacher J, Zhu X, et al. Intravenous Busulfan-Based
Myeloablative Conditioning Regimens Prior to Hematopoietic Cell
Transplantation for Hematologic Malignancies. Biol Blood Marrow
Transplant . 2016;22(8):1424-1430. doi:10.1016/j.bbmt.2016.04.013
- Kebriaei P, Bassett R, Lyons G, et al. Clofarabine Plus Busulfan is an
Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell
Transplantation in Patients with Acute Lymphoblastic Leukemia:
Long-Term Study Results. Biol Blood Marrow Transplant .
2017;23(2):285-292. doi:10.1016/j.bbmt.2016.11.001
- Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative
regimens in transplants for children with acute lymphoblastic
leukemia. J Clin Oncol . 2000;18(2):340-347.
doi:10.1200/JCO.2000.18.2.340
- Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells
versus bone marrow from unrelated donors. N Engl J Med .
2012;367(16):1487-1496. doi:10.1056/NEJMoa1203517
- Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan
dose adjustment in children [published correction appears in Bone
Marrow Transplant. 2003 Apr;31(8):729]. Bone Marrow
Transplant . 2000;26(11):1143-1147. doi:10.1038/sj.bmt.1702700
- Pulsipher MA, Langholz B, Wall DA, et al. Risk factors and timing of
relapse after allogeneic transplantation in pediatric ALL: for whom
and when should interventions be tested?. Bone Marrow
Transplant . 2015;50(9):1173-1179. doi:10.1038/bmt.2015.103
- Handgretinger R, Lang P. Could (should) we abandon total body
irradiation for conditioning in children with leukemia. Blood
Rev . 2022;56:100966. doi:10.1016/j.blre.2022.100966
- Langenhorst JB, van Kesteren C, van Maarseveen EM, et al. Fludarabine
exposure in the conditioning prior to allogeneic hematopoietic cell
transplantation predicts outcomes. Blood Adv .
2019;3(14):2179-2187. doi:10.1182/bloodadvances.2018029421.
- Dekker L, Calkoen FG, Jiang Y, et al. Fludarabine exposure predicts
outcome after CD19 CAR T-cell therapy in children and young adults
with acute leukemia. Blood Adv . 2022;6(7):1969-1976.
doi:10.1182/bloodadvances.2021006700
- Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L.
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell
Transplantation: Risk Factors for Primary Infection and Cases of
Recurrent and Late Infection at a Single Center. Biol Blood
Marrow Transplant . 2016;22(7):1275-1283.
doi:10.1016/j.bbmt.2016.04.004